| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 9 | 2025 | 41 | 5.910 |
Why?
|
| Colorectal Neoplasms | 12 | 2025 | 576 | 4.240 |
Why?
|
| Appendiceal Neoplasms | 6 | 2025 | 18 | 3.880 |
Why?
|
| Cytoreduction Surgical Procedures | 9 | 2025 | 42 | 3.470 |
Why?
|
| Hyperthermia, Induced | 5 | 2023 | 54 | 2.830 |
Why?
|
| Adenocarcinoma | 9 | 2025 | 1025 | 2.580 |
Why?
|
| Circulating Tumor DNA | 2 | 2025 | 35 | 1.740 |
Why?
|
| Microbiota | 3 | 2023 | 389 | 1.700 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2024 | 702 | 1.620 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2021 | 154 | 1.450 |
Why?
|
| Rectal Neoplasms | 4 | 2025 | 79 | 1.260 |
Why?
|
| Biomarkers, Tumor | 7 | 2025 | 1491 | 1.190 |
Why?
|
| Pancreatic Neoplasms | 4 | 2021 | 691 | 1.080 |
Why?
|
| Combined Modality Therapy | 8 | 2025 | 1239 | 1.050 |
Why?
|
| Melanoma | 5 | 2022 | 944 | 1.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2025 | 188 | 0.910 |
Why?
|
| Survival Rate | 11 | 2025 | 2057 | 0.900 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2023 | 2 | 0.850 |
Why?
|
| Hepatectomy | 1 | 2024 | 110 | 0.850 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 116 | 0.820 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 79 | 0.750 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 685 | 0.740 |
Why?
|
| Laparoscopy | 4 | 2025 | 493 | 0.720 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 79 | 0.710 |
Why?
|
| Humans | 60 | 2025 | 125014 | 0.690 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 74 | 0.680 |
Why?
|
| Appendicitis | 1 | 2021 | 127 | 0.670 |
Why?
|
| Neutropenia | 1 | 2021 | 197 | 0.660 |
Why?
|
| Mesothelioma | 1 | 2020 | 88 | 0.640 |
Why?
|
| Prognosis | 10 | 2025 | 4628 | 0.630 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 547 | 0.600 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 670 | 0.590 |
Why?
|
| Biguanides | 1 | 2017 | 13 | 0.580 |
Why?
|
| Lactams | 1 | 2017 | 19 | 0.580 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2025 | 158 | 0.570 |
Why?
|
| Digoxin | 1 | 2017 | 43 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2100 | 0.540 |
Why?
|
| Retrospective Studies | 17 | 2025 | 16307 | 0.530 |
Why?
|
| Karyopherins | 1 | 2016 | 36 | 0.520 |
Why?
|
| Longevity | 1 | 2017 | 136 | 0.520 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2016 | 118 | 0.520 |
Why?
|
| Caenorhabditis elegans | 1 | 2017 | 223 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 177 | 0.510 |
Why?
|
| Neoplasms | 6 | 2024 | 2786 | 0.490 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2022 | 89 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1252 | 0.470 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 581 | 0.470 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2020 | 376 | 0.460 |
Why?
|
| Autophagy | 1 | 2017 | 392 | 0.460 |
Why?
|
| Cell Survival | 4 | 2021 | 812 | 0.450 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 341 | 0.450 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1292 | 0.440 |
Why?
|
| Cell Nucleus | 1 | 2016 | 680 | 0.440 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2023 | 37 | 0.430 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 341 | 0.430 |
Why?
|
| Middle Aged | 19 | 2025 | 26918 | 0.430 |
Why?
|
| Carcinogenesis | 3 | 2022 | 334 | 0.410 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 1661 | 0.390 |
Why?
|
| Mutation | 6 | 2025 | 5846 | 0.390 |
Why?
|
| MAP Kinase Signaling System | 4 | 2017 | 313 | 0.380 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2025 | 723 | 0.380 |
Why?
|
| Aged | 18 | 2025 | 19854 | 0.380 |
Why?
|
| Signal Transduction | 7 | 2023 | 4531 | 0.370 |
Why?
|
| Mice | 14 | 2023 | 17625 | 0.350 |
Why?
|
| Carrier Proteins | 2 | 2006 | 1024 | 0.330 |
Why?
|
| ral GTP-Binding Proteins | 2 | 2021 | 4 | 0.320 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 207 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 350 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 488 | 0.300 |
Why?
|
| Immunity, Innate | 2 | 2011 | 373 | 0.290 |
Why?
|
| Female | 25 | 2025 | 66709 | 0.290 |
Why?
|
| Lymph Node Excision | 2 | 2024 | 166 | 0.290 |
Why?
|
| Lymphatic Metastasis | 3 | 2025 | 417 | 0.280 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 552 | 0.270 |
Why?
|
| Animals | 16 | 2023 | 34210 | 0.270 |
Why?
|
| Male | 21 | 2025 | 61429 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2004 | 207 | 0.260 |
Why?
|
| Ubiquitin | 2 | 2004 | 142 | 0.260 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2024 | 98 | 0.260 |
Why?
|
| Microsatellite Instability | 2 | 2025 | 36 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 883 | 0.250 |
Why?
|
| Adult | 12 | 2025 | 29620 | 0.250 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2023 | 35 | 0.250 |
Why?
|
| Lysosomes | 2 | 2017 | 237 | 0.240 |
Why?
|
| Liquid Biopsy | 1 | 2025 | 14 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1140 | 0.240 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2024 | 8 | 0.240 |
Why?
|
| HeLa Cells | 3 | 2017 | 806 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 359 | 0.230 |
Why?
|
| SUMO-1 Protein | 1 | 2004 | 8 | 0.230 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 5168 | 0.230 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 21 | 0.220 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2025 | 200 | 0.220 |
Why?
|
| Xenopus Proteins | 1 | 2004 | 61 | 0.220 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 663 | 0.220 |
Why?
|
| RNA Interference | 3 | 2016 | 503 | 0.220 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 1695 | 0.220 |
Why?
|
| ras Proteins | 1 | 2004 | 137 | 0.210 |
Why?
|
| Operating Rooms | 1 | 2023 | 69 | 0.210 |
Why?
|
| Dysbiosis | 1 | 2024 | 122 | 0.210 |
Why?
|
| Immunotherapy | 3 | 2022 | 675 | 0.200 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 414 | 0.200 |
Why?
|
| Surgical Stapling | 1 | 2022 | 19 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 151 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2024 | 379 | 0.190 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 88 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 6595 | 0.190 |
Why?
|
| Peritoneum | 1 | 2022 | 37 | 0.190 |
Why?
|
| Immune System | 1 | 2022 | 89 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2022 | 361 | 0.190 |
Why?
|
| Dietary Fiber | 1 | 2021 | 75 | 0.190 |
Why?
|
| Anastomosis, Surgical | 1 | 2022 | 172 | 0.190 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 61 | 0.180 |
Why?
|
| Platinum Compounds | 1 | 2020 | 6 | 0.180 |
Why?
|
| Pemetrexed | 1 | 2020 | 9 | 0.180 |
Why?
|
| Suture Techniques | 1 | 2022 | 195 | 0.180 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2021 | 44 | 0.180 |
Why?
|
| Perfusion | 1 | 2022 | 207 | 0.180 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 3345 | 0.180 |
Why?
|
| Portal Vein | 1 | 2021 | 94 | 0.170 |
Why?
|
| Enzyme Activation | 4 | 2006 | 628 | 0.170 |
Why?
|
| Thrombospondin 1 | 1 | 2020 | 23 | 0.170 |
Why?
|
| Bacteria | 1 | 2024 | 484 | 0.170 |
Why?
|
| Emergencies | 1 | 2021 | 170 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 128 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 54 | 0.170 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 48 | 0.170 |
Why?
|
| Viruses | 1 | 2021 | 123 | 0.170 |
Why?
|
| Oncogenes | 1 | 2020 | 167 | 0.170 |
Why?
|
| Biopsy | 1 | 2023 | 1235 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 418 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2004 | 1525 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 293 | 0.160 |
Why?
|
| Gene Expression | 1 | 2004 | 1561 | 0.160 |
Why?
|
| Probiotics | 1 | 2021 | 214 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 429 | 0.150 |
Why?
|
| Surgeons | 1 | 2023 | 257 | 0.150 |
Why?
|
| Down-Regulation | 1 | 2020 | 698 | 0.150 |
Why?
|
| Genomics | 2 | 2020 | 1501 | 0.150 |
Why?
|
| Starvation | 1 | 2017 | 15 | 0.150 |
Why?
|
| Autophagosomes | 1 | 2017 | 24 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1113 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2020 | 867 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 540 | 0.140 |
Why?
|
| Caloric Restriction | 1 | 2017 | 83 | 0.140 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 61 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 97 | 0.140 |
Why?
|
| Follistatin-Related Proteins | 1 | 2016 | 1 | 0.140 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2016 | 36 | 0.130 |
Why?
|
| Porphyrins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Genes, Lethal | 1 | 2016 | 76 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1895 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1397 | 0.130 |
Why?
|
| Endosomes | 1 | 2016 | 64 | 0.130 |
Why?
|
| Diet, High-Fat | 1 | 2017 | 211 | 0.130 |
Why?
|
| Fatty Liver | 1 | 2017 | 187 | 0.130 |
Why?
|
| Transfection | 2 | 2011 | 1068 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 439 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 724 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 618 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 1546 | 0.120 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2015 | 4 | 0.120 |
Why?
|
| Gene Regulatory Networks | 2 | 2024 | 351 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 1892 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 357 | 0.120 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2014 | 31 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2016 | 417 | 0.110 |
Why?
|
| HCT116 Cells | 2 | 2011 | 55 | 0.110 |
Why?
|
| Glycolysis | 1 | 2014 | 150 | 0.110 |
Why?
|
| NF-kappa B | 1 | 2016 | 459 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12383 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2023 | 6152 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2020 | 2308 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 1265 | 0.100 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 209 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2021 | 1632 | 0.100 |
Why?
|
| Mitochondria | 1 | 2017 | 682 | 0.100 |
Why?
|
| Calcium | 1 | 2017 | 1101 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3079 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2014 | 417 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 86 | 0.090 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2011 | 20 | 0.090 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 2047 | 0.090 |
Why?
|
| Cryosurgery | 1 | 2011 | 47 | 0.090 |
Why?
|
| Intestinal Obstruction | 1 | 2012 | 93 | 0.090 |
Why?
|
| Liver | 1 | 2017 | 1743 | 0.090 |
Why?
|
| Cell Line | 3 | 2004 | 2756 | 0.090 |
Why?
|
| Protein Binding | 3 | 2021 | 1757 | 0.080 |
Why?
|
| Exome | 1 | 2015 | 1033 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2011 | 192 | 0.080 |
Why?
|
| Apoptosis | 3 | 2020 | 1803 | 0.080 |
Why?
|
| Cystectomy | 1 | 2010 | 160 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2016 | 2589 | 0.080 |
Why?
|
| Catheter Ablation | 1 | 2011 | 233 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 197 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2015 | 1501 | 0.070 |
Why?
|
| Palliative Care | 1 | 2012 | 432 | 0.070 |
Why?
|
| Endoscopy | 1 | 2010 | 280 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2025 | 618 | 0.070 |
Why?
|
| Rats | 2 | 2004 | 3717 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2004 | 155 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 436 | 0.070 |
Why?
|
| Abdominal Injuries | 1 | 2007 | 110 | 0.060 |
Why?
|
| Vesicular Transport Proteins | 1 | 2006 | 120 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 557 | 0.060 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2025 | 20 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3051 | 0.060 |
Why?
|
| Protein Kinases | 2 | 2004 | 332 | 0.060 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 212 | 0.060 |
Why?
|
| Smad4 Protein | 1 | 2025 | 57 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2025 | 64 | 0.060 |
Why?
|
| Stomach | 1 | 2007 | 271 | 0.060 |
Why?
|
| Colectomy | 1 | 2025 | 74 | 0.060 |
Why?
|
| PC12 Cells | 1 | 2004 | 25 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 10 | 0.060 |
Why?
|
| Colorectal Surgery | 1 | 2004 | 10 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 18 | 0.060 |
Why?
|
| CA-125 Antigen | 1 | 2024 | 15 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2024 | 21 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2022 | 1504 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1290 | 0.060 |
Why?
|
| Neurites | 1 | 2004 | 42 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 4811 | 0.050 |
Why?
|
| Xenopus laevis | 1 | 2004 | 126 | 0.050 |
Why?
|
| Chromatography, Affinity | 1 | 2003 | 71 | 0.050 |
Why?
|
| beta Catenin | 1 | 2025 | 203 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 769 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 165 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2004 | 295 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 592 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 345 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 657 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 130 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 513 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 330 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2004 | 175 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 4403 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 90 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 50 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2002 | 76 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2004 | 276 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 120 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 228 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 35 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 33 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2004 | 1103 | 0.050 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2021 | 29 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cholangiography | 1 | 2021 | 14 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 462 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 868 | 0.050 |
Why?
|
| Cytosol | 1 | 2021 | 161 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1052 | 0.050 |
Why?
|
| Binding Sites | 1 | 2004 | 1303 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2004 | 468 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 96 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2021 | 77 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2021 | 58 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 55 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 162 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2015 | 618 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1399 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1694 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 433 | 0.040 |
Why?
|
| Proteomics | 1 | 2003 | 500 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 282 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2023 | 429 | 0.040 |
Why?
|
| Morbidity | 2 | 2012 | 248 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 565 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2006 | 3741 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 518 | 0.040 |
Why?
|
| Virus Diseases | 1 | 2021 | 280 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3892 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 1062 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 2511 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 727 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 546 | 0.040 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 37 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 1366 | 0.030 |
Why?
|
| Buffers | 1 | 2016 | 31 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 45 | 0.030 |
Why?
|
| Genome, Human | 2 | 2013 | 1274 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 79 | 0.030 |
Why?
|
| Genes, myc | 1 | 2015 | 100 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 862 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 230 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 107 | 0.030 |
Why?
|
| Risk Factors | 2 | 2025 | 10282 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 241 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 189 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 190 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1718 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 270 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 1684 | 0.030 |
Why?
|
| Systems Biology | 1 | 2013 | 57 | 0.030 |
Why?
|
| North Carolina | 1 | 2012 | 59 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3070 | 0.020 |
Why?
|
| Models, Biological | 2 | 2010 | 1461 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 361 | 0.020 |
Why?
|
| DNA Repair | 1 | 2015 | 585 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 86 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 63 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 100 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 573 | 0.020 |
Why?
|
| Laparoscopes | 1 | 2010 | 3 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2010 | 34 | 0.020 |
Why?
|
| Telomerase | 1 | 2011 | 160 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 204 | 0.020 |
Why?
|
| Urinary Diversion | 1 | 2010 | 43 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 344 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 359 | 0.020 |
Why?
|
| Pelvis | 1 | 2010 | 71 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 71 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 950 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2010 | 212 | 0.020 |
Why?
|
| United States | 1 | 2025 | 10905 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2010 | 290 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1758 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1274 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1096 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 599 | 0.020 |
Why?
|
| Time Factors | 2 | 2011 | 6326 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 760 | 0.020 |
Why?
|
| Shock, Traumatic | 1 | 2007 | 7 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 1016 | 0.020 |
Why?
|
| Michigan | 1 | 2007 | 42 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2007 | 86 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 810 | 0.020 |
Why?
|
| Urban Population | 1 | 2007 | 226 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 77 | 0.010 |
Why?
|
| Streptavidin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Biotinylation | 1 | 2003 | 22 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1707 | 0.010 |
Why?
|
| Microspheres | 1 | 2003 | 70 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1629 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 321 | 0.010 |
Why?
|
| Laparotomy | 1 | 2004 | 135 | 0.010 |
Why?
|
| Sorbitol | 1 | 2002 | 8 | 0.010 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2002 | 11 | 0.010 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2002 | 45 | 0.010 |
Why?
|
| RNA, Double-Stranded | 1 | 2002 | 63 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 95 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 111 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 311 | 0.010 |
Why?
|
| Proteome | 1 | 2003 | 243 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 539 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 293 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3570 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 1307 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 774 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 3137 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 3454 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 13978 | 0.010 |
Why?
|
| Adolescent | 1 | 2007 | 19320 | 0.000 |
Why?
|
| Child | 1 | 2007 | 24339 | 0.000 |
Why?
|